- Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
- Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
- Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
More ▼
Key statistics
As of last trade Poseida Therapeutics Inc (PSTX:NSQ) traded at 2.97, -30.56% below its 52-week high of 4.27, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.01 |
---|---|
High | 3.01 |
Low | 2.99 |
Bid | 2.96 |
Offer | 2.97 |
Previous close | 2.97 |
Average volume | 466.17k |
---|---|
Shares outstanding | 96.96m |
Free float | 70.13m |
P/E (TTM) | -- |
Market cap | 287.96m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of May 28 2024 15:52 BST.
More ▼